Use access key #2 to skip to page content.
$0.38 -0.02 (-4.98%)
7/3/2008 12:58 PM

Critical Therapeutics, Inc. (CRTX)

CAPS Rating:
*****

A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

CRTX doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

26 Outperforms
2 Underperforms
 

All-Stars

4 Outperforms
1 Underperforms
 

Players bullish on CRTX are also bullish on:

Players bearish on CRTX are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (293)
Suggest a tag

Critical Therapeutics, Inc. At A Glance

Current Price: $0.38
Last Trade Time: 7/3/2008 12:58 PM
Open: $0.00
Previous Close: $0.40
Daily Range: $0.37 - $0.41
52-Week Range: $0.26 - $2.70
Volume: 44,693
Market Cap: $17.39M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

CRTX VS S&P 500 (SPY)

CRTX 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for CRTX.

Top Bull Pitch

Recs

2

Critical Therapeutics, Inc. (CRTX)

Avatar spikenailz (76.69) Submitted: 7/26/07 10:42 AM

They have had huge success with their asthma meds and they have some new ones in late stages of trials. This company has no where to go but up.

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 7 :   1 2 Next »

Recs

0

 (CRTX)

Avatar jegray88 (< 20) Submitted: 10/17/07 12:16 PM : Outperform Start Price: $2.40 CRTX Score: -66.10

Recent gov't approval for a sustained release asthma medication. Young company partnering with older more stabilized companies to work on innovations in medicine.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CRTX)

Avatar romad829 (20.86) Submitted: 8/15/07 8:47 PM : Outperform Start Price: $2.46 CRTX Score: -74.91

Will go up post fall season.

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (CRTX)

Avatar spikenailz (76.69) Submitted: 7/26/07 10:42 AM : Outperform Start Price: $2.30 CRTX Score: -67.67

They have had huge success with their asthma meds and they have some new ones in late stages of trials. This company has no where to go but up.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CRTX)

Avatar kevinnail (< 20) Submitted: 7/26/07 9:41 AM : Outperform Start Price: $2.31 CRTX Score: -67.86

They have some awesome asthma meds on the market and other stuff in the pipeline coming on board in the near future.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (CRTX)

Avatar jupamc (< 20) Submitted: 6/19/07 3:30 PM : Outperform Start Price: $2.36 CRTX Score: -66.37

Expect major revenue increases starting 2H07 due to increase of effective salesforce from 20 to 240 with Dey partnership and new reformulation of zileuton (ZyFlo CR). May see some earlier rev. uptick due to co-marketing started in Q2. New formulation is a feasible alternative advantage to Singulair, which some people are reporting, produces side effects such as depression, anxiety.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 7 :   1 2 Next »

Wall Street

There are no Wall Street player picks.

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners